Your browser doesn't support javascript.
loading
Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study.
Shimada, Tatsuya; Higashida-Konishi, Misako; Izumi, Keisuke; Hama, Satoshi; Oshige, Tatsuhiro; Oshima, Hisaji; Okano, Yutaka.
Afiliación
  • Shimada T; Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Higashida-Konishi M; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 1608582, Japan.
  • Izumi K; Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Hama S; Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. izz@keio.jp.
  • Oshige T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 1608582, Japan. izz@keio.jp.
  • Oshima H; Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Okano Y; Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Sci Rep ; 12(1): 20926, 2022 12 03.
Article en En | MEDLINE | ID: mdl-36463264
ABSTRACT
Immunosuppressive treatment is a common cause of cytomegalovirus (CMV) reactivation. However, there is no consensus regarding the risk factors for CMV reactivation in rheumatic diseases. Therefore, this study aimed to elucidate the risk factors associated with CMV reactivation. We retrospectively collected the data of 472 patients with rheumatic diseases whose CMV pp65 antigen (C7-HRP) titer was measured. We divided the patients into those with and those without C7-HRP. We retrospectively collected data on age, sex, primary condition and organ involvement, and blood test results. We also investigated the use of immunosuppressants and the maximum and cumulative doses of prednisolone (PSL). We performed univariate and multivariate analyses to identify risk factors for CMV reactivation. Multivariate analysis showed that higher age (71.2 vs. 64.4 years, p = 0.0022), hypoalbuminemia (2.9 vs. 3.4 g/dL, p = 0.0104), higher creatinine level (1.2 vs. 0.9 mg/dL, p = 0.0026), cyclosporine use (8.2 vs. 3.6%, p = 0.0101), and higher maximum (552.4 vs. 243.3 mg, p < 0.0001) and cumulative (2785.9 vs. 1330.5 mg, p < 0.0001) doses of PSL were associated with CMV reactivation. Older age, hypoalbuminemia, higher creatinine level, cyclosporine use, and higher maximum and cumulative doses of PSL were significant risk factors for CMV reactivation in rheumatic diseases.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Reumáticas / Infecciones por Citomegalovirus / Ciclosporinas / Hipoalbuminemia Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Reumáticas / Infecciones por Citomegalovirus / Ciclosporinas / Hipoalbuminemia Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Japón